We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amorsa Therapeutics announced its patent application for deuterated norketamine and related NMDA receptor modulators was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO).....